Senior Consultant, Infectious Diseases, Fortis Memorial Research Institute, Gurgaon
Series overview · 9 articles
Tuberculosis and HIV
September 6, 2026
Tuberculosis and HIV are two of the most common infections a general physician will encounter, and each one raises the risk of the other. This guide is based on a Jivo Masterclass by Dr. Neha Rastogi Panda, Senior Consultant in Infectious Diseases at Fortis Memorial Research Institute, Gurgaon, and draws on her own clinic cases to explain how HIV is diagnosed, how a treatment regimen is actually chosen for a real patient, and why tuberculosis and HIV together create a burden neither disease creates alone.
Why Tuberculosis and HIV Are Called Double Trouble
HIV and tuberculosis reinforce each other in both directions. Having tuberculosis roughly doubles the likelihood of also having HIV, and the reverse holds too: HIV raises the risk of tuberculosis, and of tuberculosis appearing in more varied and drug-resistant forms. HIV breaches the body's mucosal barriers and lowers immunity, which increases the chance of acquiring tuberculosis, while tuberculosis complicates HIV care because the standard anti-tubercular drug rifampicin has significant interactions with antiretroviral therapy. Globally, about one in ten tuberculosis cases and more than a quarter of tuberculosis deaths occur in people who are also HIV-positive.
What This Series Covers
This series works through HIV care the way it actually happens in a clinic: recognising early infection and choosing the right test at the right time, building an antiretroviral regimen around a specific patient rather than a generic protocol, using pre-exposure and post-exposure prophylaxis to prevent new infections, protecting a baby when the mother is HIV-positive, recognising when a regimen has genuinely failed, and where long-acting therapy and cure research are headed. One article is given entirely to the tuberculosis and HIV co-infection case that anchors this masterclass, since it is where the two conditions this series is named for actually meet.
A Note on Scope
Dr. Rastogi Panda structured this session primarily around HIV, using a tuberculosis co-infection case as the bridge between the two conditions, and closed by proposing a dedicated follow-up session on tuberculosis itself. This series reflects that scope faithfully: it goes deep on HIV diagnosis, treatment and prevention, and covers tuberculosis specifically where it intersects with HIV, rather than as a separate standalone curriculum.
This guide is based on a live Jivo Masterclass: Dr. Neha Rastogi Panda taught doctors across Africa on March 30, 2025.
FROM THE LIVE Q&A
Dr. Emanuela
What are the early signs of HIV?
Dr. Neha Rastogi Panda
The early signs, known as acute HIV syndrome, look like a flu. Most patients who are symptomatic present with intermittent fever for two to three months, fatigue or weakness, weight loss, loss of appetite, cough, cold, sore throat, more frequent minor illnesses than usual, and loose motions or diarrhoea. This symptom complex over the first month or two is what we call acute HIV syndrome.
Book a Consultation with Dr. Neha Rastogi Panda
Book on WhatsAppOr message us on WhatsApp: +91 98182 98669
Frequently Asked Questions
Why don't we use the urine LAM test and stool test for all patients?▼
The urine lipoarabinomannan (LAM) test is reserved for tuberculosis diagnosis, and it has only been validated for patients with a CD4 count below 100. Below that threshold, a high tuberculosis bacterial burden allows the antigen to wash out into the urine; above it, the test loses sensitivity and specificity, so extrapolating it to every patient isn't supported. On stool testing for other opportunistic infections, a high viral load before treatment changes the normal gut flora, so a stool sample will often show excess normal flora and candida, which makes interpreting it for treatment decisions difficult specifically in HIV patients.
Are there any antiretrovirals that can have prolonged action for up to three or six months?▼
Yes. Cabotegravir, a longer-acting integrase inhibitor, combined with rilpivirine from the non-nucleoside reverse transcriptase inhibitor family, was studied in the TANGO trial and showed viral suppression sustained for close to three months from a single dose. Their half-life runs to about 24 to 26 weeks, so the combination is given as one intramuscular or subcutaneous injection every three months for patients who are already stable on oral therapy, as maintenance rather than as a starting regimen.
At what stage can we diagnose opportunistic infections, and how do we diagnose them?▼
Opportunistic infections can be diagnosed at any stage; the WHO staging system, grade one through four, is built around exactly this, using the infection profile and CD4 level together. Oral thrush, for instance, usually appears at stage two, while reactive generalised lymphadenopathy sits at stage one. Sometimes the opportunistic infection is itself the first clue to an undiagnosed HIV infection, tuberculosis being the clearest example: finding it usually puts the patient at WHO stage three, and a very low viral load and CD4 count below 200 to 250 lets you further risk-stratify from there. Diagnosis runs on three legs: the clinical symptoms and signs, which organ is involved, and targeted sampling, such as testing sputum by GeneXpert for suspected pulmonary tuberculosis, or testing CSF, or serum cryptococcal antigen when CSF isn't accessible, for cryptococcal meningitis.
What are the early signs of HIV?▼
The early signs, known as acute HIV syndrome, look like a flu. Most patients who are symptomatic present with intermittent fever for two to three months, fatigue or weakness, weight loss, loss of appetite, cough, cold, sore throat, more frequent minor illnesses than usual, and loose motions or diarrhoea. This symptom complex over the first month or two is what we call acute HIV syndrome.
In This Series: Tuberculosis & HIV - An Insight
- 1.Tuberculosis and HIV
- 2.How HIV Is Diagnosed: Getting the Testing Window Right
- 3.Starting Antiretroviral Therapy: Building the Regimen Around the Patient
- 4.Pre-Exposure Prophylaxis for HIV: Who Qualifies and How Well It Works
- 5.Post-Exposure Prophylaxis: Acting Within 72 Hours of a Possible HIV Exposure
- 6.Tuberculosis and HIV Co-Infection: Why the Two Diseases Compound Each Other
- 7.Preventing Mother-to-Child Transmission of HIV
- 8.When HIV Therapy Appears to Fail: Telling Adherence Problems From Real Failure
- 9.Long-Acting HIV Therapy and the Path Toward a Cure